摘要目的 探讨钙离子结合蛋白S100家族成员S100A11在非小细胞肺癌(NSCLC)组织的表达及其与临床病理特征的关系.方法 采用免疫组织化学SP法检测S100A11蛋白在112例NSCLC组织(A组)及其相应癌旁组织(B组)和10例正常肺组织(C组)的表达,分析其与NSCLC临床病理特征的关系.结果 A组S100A11蛋白低表达24例(24/112,21.4％),高表达88例(88/112,78.6％);B组S100A11蛋白均为低表达(112/112,100.0％);C组S100A11蛋白表达均为阴性表达(10/10,100.0％),3组间差异有统计学意义(x2=153.634,P＜0.001).S100A11蛋白表达水平与肿瘤的病理类型(x2=6.807 ,P =0.009)、分化程度(x2=5.029,P=0.025)和局部淋巴结转移(x2=11.721,P=0.001)有相关性,与性别(x2 =0.020,P =0.888)、年龄(x2 =0.816,P =0.366)及肿瘤大小(x2=0.406,P =0.524)无关.结论 S100A11蛋白在NSCLC组织中表达增高,与NSCLC的生物学行为特性有关,可能参与NSCLC的发生发展,有望成为NSCLC诊断、预后的潜在靶分子.

abstractsObjective To investigate the expression of S100A11 protein in non-small cell lung cancer (NSCLC) and its association with clinical and pathological characteristics.Methods The expressions of S100A11 protein in 112 NSCLC tumor tissues (group A), tumor-adjacent tissues (group B) and 10 normal lung tissues (group C) were detected by immunohistochemical SP method.The association of S100A11 expression with clinical pathological characteristics was analyzed.Results The percentage of the cases with high expression cases of S100A11 protein was 78.6％ (88/112) , and the low expression rate was 21.4 ％ (24/112) in group A.The low expression rate of S100A11 protein was 100.0％ (112/112) in group B.The negative expression rate of S100A11 protein was 100.0％ (10/10) in group C.The difference of S100A11 expression among the three groups was statistically significant (x2 =153.634, P ＜0.001).The S100A11 expression was associated with pathological type (x2 =6.807, P =0.009), differentiated degree (x2 =5.029, P =0.025), regional lymph node metastasis (x2 =11.721, P =0.001) in NSCLC, but it was not associated with gender (x2 =0.020, P =0.888) , age (x2 =0.816, P =0.366) and tumor size (x2 =0.406, P =0.524).Conclusion S100A11 is highly expressed in NSCLC, which is closely related with biological behavioral characteristics.S100A11 may participate in the occurrence and development of NSCLC, and it is expected to become the potential target of diagnosis and prognosis in patients with NSCLC.